Contradictions Unveiled: Medicaid Impact and Rhode Island Growth in American Shared Hospital Services' Q2 2025 Call
Generado por agente de IAAinvest Earnings Call Digest
miércoles, 13 de agosto de 2025, 2:30 pm ET1 min de lectura
Impact of Medicaid reimbursement changes, expansion in Rhode Island and facility synergies, staffing and operational capacity in Rhode Island centers, marketing efforts in Rhode Island are the key contradictions discussed in American Shared Hospital Services' latest 2025Q2 earnings call
Revenue Growth and Operational Strategy:
- American Shared Hospital Services reported second quarter 2025 revenue of $7.1 million, a 16% increase from the previous quarter and a slight increase compared to Q2 2024.
- This growth was driven by the expansion of the Direct Patient Services segment, including the acquisition of radiation therapy centers in Rhode Island and the opening of a new treatment center in Puebla, Mexico.
Gamma Knife and Proton Beam Radiation Therapy:
- Gamma Knife revenue increased 25% quarter-over-quarter to $2.6 million in Q2 2025, while proton beam therapy revenue grew 17% to $1.9 million.
- The growth in Gamma Knife revenue is attributed to increased utilization of Gamma Knife systems by health system customers, while the decline in proton beam therapy revenue is due to normal cyclical fluctuations.
International Business Expansion:
- The company's international business segment represents a large growth opportunity, with treatments expanding in countries like Peru and Ecuador, and new centers in Guadalajara and Puebla, Mexico.
- This growth is supported by the establishment of the fourth international center in Guadalajara, Mexico, which will be the only S3 Gamma Knife center in a country of 130 million people.
Financial Performance and Outlook:
- Q2 2025 adjusted EBITDA was $1.7 million, compared to $949,000 in Q1 2025 and $2 million in Q2 2024.
- Despite a decline in gross margin and operating income due to lower Gamma Knife volumes and increased operational expenses, the company remains confident in its long-term growth strategy and has a strong balance sheet.

Revenue Growth and Operational Strategy:
- American Shared Hospital Services reported second quarter 2025 revenue of $7.1 million, a 16% increase from the previous quarter and a slight increase compared to Q2 2024.
- This growth was driven by the expansion of the Direct Patient Services segment, including the acquisition of radiation therapy centers in Rhode Island and the opening of a new treatment center in Puebla, Mexico.
Gamma Knife and Proton Beam Radiation Therapy:
- Gamma Knife revenue increased 25% quarter-over-quarter to $2.6 million in Q2 2025, while proton beam therapy revenue grew 17% to $1.9 million.
- The growth in Gamma Knife revenue is attributed to increased utilization of Gamma Knife systems by health system customers, while the decline in proton beam therapy revenue is due to normal cyclical fluctuations.
International Business Expansion:
- The company's international business segment represents a large growth opportunity, with treatments expanding in countries like Peru and Ecuador, and new centers in Guadalajara and Puebla, Mexico.
- This growth is supported by the establishment of the fourth international center in Guadalajara, Mexico, which will be the only S3 Gamma Knife center in a country of 130 million people.
Financial Performance and Outlook:
- Q2 2025 adjusted EBITDA was $1.7 million, compared to $949,000 in Q1 2025 and $2 million in Q2 2024.
- Despite a decline in gross margin and operating income due to lower Gamma Knife volumes and increased operational expenses, the company remains confident in its long-term growth strategy and has a strong balance sheet.

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema



Comentarios
Aún no hay comentarios